BIOPHTA is a preclinical-stage biotech company transforming ophthalmology to relieve patients in the treatment of their eye diseases. BIOPHTA develops a new standard of care to replace topical eye-drops as well as invasive intra-ocular injections for the retina.
The technology is based on an innovative family of biopolymers that improves the efficacy of eye medications by leveraging the first 7-day continuous microdosing pharmaceutical form. BIOPHTA’s topical and self-applied treatment overcomes the efficacy issues of daily eyedrops as well as high cost & invasiveness of ocular injections. It’s the first time a therapy displays such innovative technological features to disrupt both front-of-the-eye as well as retina treatments.
Find out more about BIOPHTA: www.biophta.com